Results 11 to 20 of about 178,362 (241)
Arsenic trioxide as a novel anti-glioma drug: a review
Cellular & Molecular Biology Letters, 2020 Arsenic trioxide has shown a strong anti-tumor effect with little toxicity when used in the treatment of acute promyelocytic leukemia (APL). An effect on glioma has also been shown.
Yi Fang, Zhen Zhang
doaj +2 more sources
Advanced Science, 2019 The latent viral reservoir is the source of viral rebound after interruption of antiretroviral therapy (ART) and is the major obstacle in eradicating the latent human immunodeficiency virus‐1 (HIV‐1).
Qing Yang +16 more
doaj +2 more sources
Haematologica, 2020 Daily intravenous arsenic trioxide administered with all-trans retinoid acid, the standard-of-care for acute promyelocytic leukemia, is costly and challenging to administer.
Farhad Ravandi +13 more
doaj +2 more sources
Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers [PDF]
Journal of Biomedical Research, 2017 Since arsenic trioxide (ATO) was first approved as the front line therapy for acute promyelocytic leukemia (APL) 25 years ago, its anti-cancer properties for various malignancies have been under intense investigation.
Akhtar, Anam +4 more
core +2 more sources
Cell Death and Disease, 2021 Inducing autophagy and inhibiting apoptosis may provide a therapeutic treatment for atherosclerosis (AS). For the treatment of progressive AS, arsenic trioxide (ATO) has been used to coat vascular stents.
S. Fang +10 more
semanticscholar +1 more source
Current Advances of Nanomedicines Delivering Arsenic Trioxide for Enhanced Tumor Therapy
Pharmaceutics, 2022 Arsenic trioxide (ATO) is one of the first-line chemotherapeutic drugs for acute promyelocytic leukemia. Its anti-cancer activities against various human neoplastic diseases have been extensively studied. However, the clinical use of ATO for solid tumors
Meng-Jia Yu +4 more
semanticscholar +1 more source
JAMA Oncology, 2021 Importance All-trans retinoic acid (ATRA) and arsenic trioxide therapy without the use of maintenance therapy has been found to be beneficial for the treatment of adults with standard-risk acute promyelocytic leukemia (APL).
M. Kutny +15 more
semanticscholar +1 more source
Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors
Medicinal research reviews (Print), 2021 Despite having a rich history as a poison, arsenic and its compounds have also gained a great reputation as promising anticancer drugs. As a pioneer, arsenic trioxide has been approved for the treatment of acute promyelocytic leukemia.
Marthe Sönksen, K. Kerl, Hana Bunzen
semanticscholar +1 more source
Toxicology and Applied Pharmacology, 2022 Environmental arsenic exposure is associated with lung cancer. Arsenic is the first substance known to cause lung cancer by two distinct routes, ingestion and inhalation, in the forms of soluble arsenite and particulate arsenic trioxide, respectively. In
K. Cooper, R. Liu, Xixi Zhou
semanticscholar +1 more source
Arsenic trioxide targets Hsp60, triggering degradation of p53 and survivin
Chemical Science, 2021 The mechanisms of action of arsenic trioxide (ATO), a clinically used drug for the treatment of acute promyelocytic leukemia (APL), have been actively studied mainly through characterization of individual putative protein targets.
Xuqiao Hu +14 more
semanticscholar +1 more source